[
  {
    "ts": null,
    "headline": "CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU",
    "summary": "CRISPR Therapeutics and Sirius dose the first patient in a phase II study of SRSD107 for thromboembolic disorders in Europe.",
    "url": "https://finnhub.io/api/news?id=a73a716232e8a77fa1a9f0f9ea9bd4aa2e999d9bc2118bcac7e90e7113da090f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758643680,
      "headline": "CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU",
      "id": 136853069,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "CRISPR Therapeutics and Sirius dose the first patient in a phase II study of SRSD107 for thromboembolic disorders in Europe.",
      "url": "https://finnhub.io/api/news?id=a73a716232e8a77fa1a9f0f9ea9bd4aa2e999d9bc2118bcac7e90e7113da090f"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain",
    "summary": "BOSTON, September 23, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with basketball world champion Jayson Tatum to raise awareness of JOURNAVX® (suzetrigine), a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain in adults and the first new class of pain medicine approved in more than 20 years.",
    "url": "https://finnhub.io/api/news?id=dcbeecfdea6c15c4ae486f26a2e6cc1d15a4c10f8e729f94d74de1fafc7e4b41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758632400,
      "headline": "Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain",
      "id": 136851111,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, September 23, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with basketball world champion Jayson Tatum to raise awareness of JOURNAVX® (suzetrigine), a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain in adults and the first new class of pain medicine approved in more than 20 years.",
      "url": "https://finnhub.io/api/news?id=dcbeecfdea6c15c4ae486f26a2e6cc1d15a4c10f8e729f94d74de1fafc7e4b41"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bank of America Global Healthcare Conference 2025 Transcript",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bank of America Global Healthcare Conference 2025 September 23, 2025 3:10 AM EDTCompany ParticipantsSusie...",
    "url": "https://finnhub.io/api/news?id=d971661b5bd8e3db5f62fdcd4245ca292dab51b9c24e292b289f557ba322aaf8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758614028,
      "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Presents at Bank of America Global Healthcare Conference 2025 Transcript",
      "id": 136849010,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bank of America Global Healthcare Conference 2025 September 23, 2025 3:10 AM EDTCompany ParticipantsSusie...",
      "url": "https://finnhub.io/api/news?id=d971661b5bd8e3db5f62fdcd4245ca292dab51b9c24e292b289f557ba322aaf8"
    }
  },
  {
    "ts": null,
    "headline": "Unpacking Q2 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks",
    "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Vertex Pharmaceuticals (NASDAQ:VRTX).",
    "url": "https://finnhub.io/api/news?id=56b84fc5018094a884cf522a41f3c3235fffbfc81180e33349a114f207dc5829",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758598424,
      "headline": "Unpacking Q2 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks",
      "id": 136851112,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Vertex Pharmaceuticals (NASDAQ:VRTX).",
      "url": "https://finnhub.io/api/news?id=56b84fc5018094a884cf522a41f3c3235fffbfc81180e33349a114f207dc5829"
    }
  }
]